Naporafenib : ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor

Brepocitinib : Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis

Defactinib: Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma